about
Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophyProlonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002Amino acids for amyotrophic lateral sclerosis / motor neuron diseaseAmino acids for amyotrophic lateral sclerosis / motor neuron diseaseMechanical ventilation for amyotrophic lateral sclerosis/motor neuron diseaseIdentification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinaseALS2/Alsin regulates Rac-PAK signaling and neurite outgrowthRiluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS studyRecent advances in amyotrophic lateral sclerosisIntron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosisp35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interactionTDP-43 mutations in familial and sporadic amyotrophic lateral sclerosisAbsence of cognitive, behavioral, or emotional dysfunction in progressive muscular atrophyNEK1 variants confer susceptibility to amyotrophic lateral sclerosisSafety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialThe economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United KingdomReduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosisAge of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and comparison with published loci.Biomarkers in amyotrophic lateral sclerosis.Latent cluster analysis of ALS phenotypes identifies prognostically differing groupsComparison of the King's and MiToS staging systems for ALS.Motor neuron disease and its management.The anatomy of cognitive impairment in amyotrophic lateral sclerosis: more than frontal lobe dysfunction.Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q.Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysisFunctional magnetic resonance imaging of verbal fluency and confrontation naming using compressed image acquisition to permit overt responses.Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS.Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study.Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsyLithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.Automated, high accuracy classification of Parkinsonian disorders: a pattern recognition approach.Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis.Differential corticospinal tract degeneration in homozygous 'D90A' SOD-1 ALS and sporadic ALS.A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliabilityThe association between ALS and population density: A population based studyThe management of motor neurone disease.
P50
Q21142744-EE6AB12D-0F4C-4430-8B5E-37BED99E081CQ22306532-FA837BE7-35EA-45A5-ABE6-1B873D10EF14Q24243319-C0E1899F-9CE9-4222-9A29-C71620217595Q24247715-5C195741-2C7E-48D5-A75A-A049B32CA5CDQ24247818-18E4F73D-4AF8-408E-96CD-13BABB849D1AQ24306518-FDB06B45-E2D2-4475-B50A-96245AE893FDQ24310305-6ECA6EF8-AD9D-40ED-85B2-1381ADEAF52BQ24655620-AB6A53D7-1735-42F0-92F2-3CE1EF335DFBQ28145233-00F20309-0577-4D3B-8F70-17F97390AD28Q28189509-8BE8A076-1939-4EFA-A21D-A8F2D24619E9Q28199719-CA6F441A-6702-4BFC-8F2C-6595B4181F2BQ28270779-D1946475-942E-456E-8FE0-3B6D009D3C47Q28273822-1265AB2C-9070-49BC-8ADE-AB7431EEF3B9Q28277378-E078CC45-FD47-48A4-A16B-20B9C65BA5B8Q28538939-A4D2FBDC-131C-4912-9CF9-54ED8710A948Q28740556-4F8BB69A-B6C8-41EE-9F2A-1C13FC5A29E5Q28943310-47E7E225-7411-4FD8-BB42-36D41CE51FCDQ29417029-F472EA7B-FFFD-4C24-BF1B-400FDF1C84FEQ30975356-C8B9E3D6-3EC0-4949-862B-2A4EAE40EE54Q33392844-C20C6E49-160F-4446-B7A5-0A7F0BC04738Q33505666-CD6D4A5E-189A-4B2E-BAAE-0968F5EF7102Q33659132-DDDA52D4-0431-4B10-B1BB-67FC6AC26879Q33685417-6AEE617C-99CA-4A33-9C2F-650E3FBA3700Q33844053-19EBD249-CB46-4398-AB39-EE52465693C7Q33905226-9BA7A392-9FBA-488E-A637-D620DAF14AF1Q34026859-6AC1AF37-5D93-4CFE-8156-0C4C8E89BEC2Q34063137-A3DE9F44-6C51-4900-8565-5D8079B9F3D4Q34227535-C44883B2-1C50-4C33-87B5-0146A8D4330CQ34235637-960A011B-ACD9-4A08-A88A-97C1BBEC9410Q34327603-9ED94766-73C7-4DAE-A810-841B258F331AQ34340508-F2B3FCEE-9B06-4F44-963A-407CF946882CQ34535482-7E4FC177-6000-41F8-B032-994C4368D0DBQ34612291-4DA73C44-13F7-4A5F-AA0E-7DC1FA85CF2BQ34648924-1482BC85-1CD2-4B5F-9ED7-8AAF6267985FQ34838098-9DB3CD9B-F0C2-4A6A-97D6-81BBC3028A2EQ35001476-D6C40168-DE71-473E-BE36-A851B4E89E50Q35098534-1B0C4571-B1CF-4573-8E53-F78A97436E86Q35154822-8C526F2D-6C59-4851-8480-06B6247DEC72Q35491762-A414A581-5E77-4DE5-AFE8-EF986B0E8811Q35576475-8ADA541A-BE2A-495E-B557-595227122B03
P50
description
onderzoeker
@nl
name
P Nigel Leigh
@ast
P Nigel Leigh
@en
P Nigel Leigh
@es
P Nigel Leigh
@nl
type
label
P Nigel Leigh
@ast
P Nigel Leigh
@en
P Nigel Leigh
@es
P Nigel Leigh
@nl
altLabel
P N Leigh
@en
prefLabel
P Nigel Leigh
@ast
P Nigel Leigh
@en
P Nigel Leigh
@es
P Nigel Leigh
@nl